PDL BIOPHARMA, INC. Form 8-K
February 07, 2014
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
FORIVI 6-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 7, 2014
PDL BioPharma, Inc.
(Exact name of Company as specified in its charter)
000-19756
(Commission

File Number)					
Delaware (State or Other Jurisdiction	94-3023969 (LR S. Employer				
of Incorporation)	Identification No.)				
932 Southwood Boulevard					
Incline Village, Nevada 894	51				
(Address of principal execut	nve offices, with zip code)				
(775) 832-8500					
(Company's telephone number, including area code)					
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:					
1 3					
Written communications purs	suant to Rule 425 under the Securities Act (17 CFR 230.425)				
Soliciting material pursuant to	o Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)				
Something material parsuant t	o Ruie 11a 12 ander the Exchange 11et (17 et 11 2 tot 1 ta 12)				
Pre-commencement commun	ications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))				
Pre-commencement commun	ications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))				

## Edgar Filing: PDL BIOPHARMA, INC. - Form 8-K

Item 8	8.01	Other	Events.
--------	------	-------	---------

On February 7, 2014, PDL BioPharma, Inc. (the "Company") issued a press release announcing the pricing of an offering of its 4.00% Convertible Senior Notes due February 1, 2018. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

## Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

**Exhibit No. Description** 

99.1 Press Release

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC. (Company)

By: /s/ Peter S. Garcia

Peter S. Garcia Vice President and Chief Financial Officer

Dated: February 7, 2014

## **EXHIBIT INDEX**

**Exhibit No. Description** 99.1 Press Release